Form D · Biotechnology
Immix Biopharma, Inc.
Los Angeles, CA · CIK 0001873835
Offering snapshot reported May 20, 2024 · SEC filing
- Reported sold
- $0 Indefinite offering
- Investors reported
- 14 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- May 20, 2024 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| May 20, 2024 | Initial | $0 | No comparison | 14 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- Yes
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-513789
This Form D relates to the Issuer's issuance of shares of its common stock in connection with the acquisition of the minority interest not already owned by the Issuer in its greater than 95% owned subsidiary, Nexcella, Inc., via short form merger
Sales compensation recipients
Scroll to see all columns →
| Recipient | CRD | Associated broker-dealer |
|---|---|---|
| None | None |
Source: Form D, filed May 20, 2024. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Helen C. Adams | Director |
| Jane Buchan | Director |
| Yekaterina Chudnovsky | Director |
| Jason Hsu | Director |
| Magda Marquet | Director |
| Gabriel Morris | Director, Executive |
| Carey Ng | Director |
| Ilya Rachman | Director, Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
11400 W Olympic Blvd Suite 200
Los Angeles, CA, 90064
Los Angeles, CA, 90064